OBJECTIVE: To better define early and long-term outcomes of patients undergoing thoracic metastasectomy for thyroid cancer. METHODS: We identified, reviewed, and analyzed the medical records of all patients who underwent thoracic metastasectomy for thyroid cancer in our institution from 1971 to 2006. RESULTS: There were 48 patients (25 men, 23 women). A complete resection (R0) of all known disease was performed in 33 (69%) patients, while 15 (31%) underwent incomplete resection (R1 or R2). By histology, the majority were papillary 31 (65%), follicular 8 (17%), medullary 5 (10%), and Hürthle cell 4 (8%). Ninety percent were confined to a single side of the chest, with 10% presenting with bilateral metastases. Thoracotomy was performed in 28 (58%), sternotomy in 12 (25%), and thoracoscopy was used in 8 (17%). Operative mortality was zero and postoperative complications occurred in 8 patients (17%). There are currently 18 surviving patients from the cohort (37%) with a median follow-up of 10 years (range, 1 month to 17 years). The overall 5-year survival after thoracic metastasectomy was 60%. Based on histology, 5-year survival for papillary cancer was 64% compared to 37% for follicular and Hürthle cell neoplasms (p=0.03). All five medullary thyroid cancer patients were alive at 5 years. Five-year survival was also improved for patients less than 45 years old at the time of diagnosis of their initial thyroid malignancy (94% vs 49%; p=0.03). Disease-free interval of >3 years between initial thyroid malignancy diagnosis and thoracic metastasectomy demonstrated improved 5-year survival (67% vs 52%; p=0.01). CONCLUSION: Pulmonary resection for thyroid metastasis is safe with low morbidity and mortality. Retrospective analysis demonstrates improved long-term survival in patients with papillary histology, longer disease-free interval (>3 years) and younger age at diagnosis of initial thyroid malignancy. Excellent long-term survival was also achievable in selected patients with medullary thyroid metastasis.
OBJECTIVE: To better define early and long-term outcomes of patients undergoing thoracic metastasectomy for thyroid cancer. METHODS: We identified, reviewed, and analyzed the medical records of all patients who underwent thoracic metastasectomy for thyroid cancer in our institution from 1971 to 2006. RESULTS: There were 48 patients (25 men, 23 women). A complete resection (R0) of all known disease was performed in 33 (69%) patients, while 15 (31%) underwent incomplete resection (R1 or R2). By histology, the majority were papillary 31 (65%), follicular 8 (17%), medullary 5 (10%), and Hürthle cell 4 (8%). Ninety percent were confined to a single side of the chest, with 10% presenting with bilateral metastases. Thoracotomy was performed in 28 (58%), sternotomy in 12 (25%), and thoracoscopy was used in 8 (17%). Operative mortality was zero and postoperative complications occurred in 8 patients (17%). There are currently 18 surviving patients from the cohort (37%) with a median follow-up of 10 years (range, 1 month to 17 years). The overall 5-year survival after thoracic metastasectomy was 60%. Based on histology, 5-year survival for papillary cancer was 64% compared to 37% for follicular and Hürthle cell neoplasms (p=0.03). All five medullary thyroid cancerpatients were alive at 5 years. Five-year survival was also improved for patients less than 45 years old at the time of diagnosis of their initial thyroid malignancy (94% vs 49%; p=0.03). Disease-free interval of >3 years between initial thyroid malignancy diagnosis and thoracic metastasectomy demonstrated improved 5-year survival (67% vs 52%; p=0.01). CONCLUSION: Pulmonary resection for thyroid metastasis is safe with low morbidity and mortality. Retrospective analysis demonstrates improved long-term survival in patients with papillary histology, longer disease-free interval (>3 years) and younger age at diagnosis of initial thyroid malignancy. Excellent long-term survival was also achievable in selected patients with medullary thyroid metastasis.
Authors: J D Lin; M J Huang; J H Juang; T C Chao; B Y Huang; K W Chen; J Y Chen; K L Li; J F Chen; Y S Ho Journal: Thyroid Date: 1999-12 Impact factor: 6.568
Authors: D Liu; D M Labow; N Dang; N Martini; M Bains; M Burt; R Downey; V Rusch; J Shah; R J Ginsberg Journal: Ann Surg Oncol Date: 1999-09 Impact factor: 5.344
Authors: James P Burke; Ian D Hay; Fiona Dignan; John R Goellner; Sara J Achenbach; Ann L Oberg; L Joseph Melton Journal: Mayo Clin Proc Date: 2005-06 Impact factor: 7.616
Authors: Ho Pak; Loukas Gourgiotis; Wen-I Chang; Lori C Guthrie; Monica C Skarulis; James C Reynolds; Maria J Merino; David S Schrump; Steven K Libutti; H Richard Alexander; Nicholas J Sarlis Journal: J Surg Oncol Date: 2003-01 Impact factor: 3.454
Authors: Ian D Hay; Tammi R Johnson; Suneetha Kaggal; Megan S Reinalda; Nicole M Iniguez-Ariza; Clive S Grant; Siobhan T Pittock; Geoffrey B Thompson Journal: World J Surg Date: 2018-02 Impact factor: 3.352